Buchumschlag

Event-free survival in patients with early HER2-positive breast cancer with a pathological complete response after HER2-targeted therapy: a pooled analysis

The standard-of-care for patients with pathological complete response (pCR) after neoadjuvant human epidermal growth factor receptor 2 (HER2)-targeted therapy plus chemotherapy is continuation of HER2-targeted therapy in the adjuvant setting. Our objective was to evaluate risk of recurrence or death...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Swain, Sandra M. (VerfasserIn) , Macharia, Harrison (VerfasserIn) , Cortes, Javier (VerfasserIn) , Dang, Chau (VerfasserIn) , Gianni, Luca (VerfasserIn) , Hurvitz, Sara A. (VerfasserIn) , Jackisch, Christian (VerfasserIn) , Schneeweiss, Andreas (VerfasserIn) , Slamon, Dennis (VerfasserIn) , Valagussa, Pinuccia (VerfasserIn) , Du Toit, Yolande (VerfasserIn) , Heinzmann, Dominik (VerfasserIn) , Knott, Adam (VerfasserIn) , Song, Chunyan (VerfasserIn) , Cortazar, Patricia (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 15 October 2022
In: Cancers
Year: 2022, Jahrgang: 14, Heft: 20, Pages: 1-14
ISSN:2072-6694
DOI:10.3390/cancers14205051
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3390/cancers14205051
Verlag, lizenzpflichtig, Volltext: https://www.mdpi.com/2072-6694/14/20/5051
Volltext
Verfasserangaben:Sandra M. Swain, Harrison Macharia, Javier Cortes, Chau Dang, Luca Gianni, Sara A. Hurvitz, Christian Jackisch, Andreas Schneeweiss, Dennis Slamon, Pinuccia Valagussa, Yolande du Toit, Dominik Heinzmann, Adam Knott, Chunyan Song and Patricia Cortazar
Beschreibung
Zusammenfassung:The standard-of-care for patients with pathological complete response (pCR) after neoadjuvant human epidermal growth factor receptor 2 (HER2)-targeted therapy plus chemotherapy is continuation of HER2-targeted therapy in the adjuvant setting. Our objective was to evaluate risk of recurrence or death in these patients and determine if outcomes differed by the HER2-targeted regimen received in each setting. We analyzed patient-level data from five randomized trials evaluating trastuzumab, pertuzumab, or both as part of systemic neoadjuvant and adjuvant therapy for HER2-positive early breast cancer, and assessed event-free survival (EFS) in 1763 patients. Patients with pCR had decreased risk of an EFS event versus those with residual disease (unadjusted hazard ratio [HR] = 0.35; 95% confidence interval [CI]: 0.27-0.46). Regardless of pCR status, after adjusting for baseline factors, reduction in EFS event risk was greater in patients administered pertuzumab/trastuzumab in both settings versus those administered only trastuzumab in both settings (HR = 0.36; 95% CI: 0.26-0.49), or pertuzumab/trastuzumab in the neoadjuvant setting and only trastuzumab in the adjuvant setting (HR = 0.67; 95% CI: 0.47-0.96). Patients with pCR had longer EFS than those with residual disease. Patients treated with pertuzumab/trastuzumab in both the neoadjuvant and adjuvant settings had the lowest risk of breast cancer recurrence.
Beschreibung:Gesehen am 18.01.2023
Beschreibung:Online Resource
ISSN:2072-6694
DOI:10.3390/cancers14205051

Ähnliche Einträge